
Sanofi
- Jurisdiction
France - LEI
549300E9PC51EN656011 - ISIN
FR0000120578 (SAN.PA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€162.33 91.7% undervalued - Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Read full profile
Fundamentals
- Net revenue
€43.13B - Gross margin
71.6% - EBIT
€11.48B - EBIT margin
26.6% - Net income
€9.13B - Net margin
21.2%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
- Last dividend amount
-
€3.92 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
52.3%
Analyst ratings
8 analysts rated this company in the past 90 days. The average target price is €110.75, this is a change of +30.8% compared to the current price.
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions